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ABSTRACT
Objectives: To explore prescribing practitioners’
perspectives on prescribed codeine use, their ability to
identify dependence and their options for treatment in
the UK.
Design: Cross-sectional design using a questionnaire
containing closed-ended and open-ended items.
Setting: A nationally representative sample of
prescribing professionals working in the UK.
Participants: 300 prescribing professionals working
in primary care and pain settings.
Results: Participants stated that they regularly
reviewed patients prescribed codeine, understood the
risks of dependence and recognised the potential for
codeine to be used recreationally. Over half the
participants felt patients were unaware of the adverse
health consequences of high doses of combination
codeine medicines. One-quarter of participants
experienced patient resentment when asking about
medicines containing codeine. Just under 40% of
participants agreed that it was difficult to identify
problematic use of codeine without being informed by
the patient and did not feel confident in identification
of codeine dependence. Less than 45% of all
participants agreed that codeine dependence could be
managed effectively in general practice. Slow or
gradual withdrawal was the most popular suggested
treatment in managing dependence. Education and
counselling was also emphasised in managing
codeine-dependent patients in primary care.
Conclusions: Communication with patients should
involve assessment of patient understanding of their
medication, including the risk of dependence. There is
a need to develop extra supports for professionals
including patient screening tools for identifying codeine
dependence. The support structure for managing
codeine-dependent patients in primary care requires
further examination.
INTRODUCTION
Pain is a common reason for accessing primary
care services. It is estimated that 14 million
people in the UK suffer from long-term pain,1
with patients presenting with headaches
thought to account for 1 in 25 of primary care
consultations,2 and musculoskeletal pain
accounting for 1 in 7.3 Opioids are widely used
in pain management with codeine being the
second most widely prescribed opioid medi-
cine in general practice.4 In 2012, it was esti-
mated that 640 codeine prescriptions per 1000
patients were dispensed in the UK.5
Additionally, medicines containing codeine
can be purchased over the counter (OTC) in
pharmacies, albeit with restrictions.6
Medicines containing codeine (up to 12.8 mg
per unit dose) may only be sold in the UK
under the supervision of a qualiﬁed pharma-
cist. There are restrictions on the quantity of
tablets permitted for sale in a single transac-
tion and the product is not available for self-
selection, although advertising of codeine-
containing medicines is permitted in the phar-
macy and on national media. A sale may be
refused if there is suspicion that the buyer is
misusing codeine. Currently, the nature and
extent of OTC codeine use and misuse in the
UK is not widely reported.
Strengths and limitations of this study
▪ This is the first study examining medical profes-
sionals’ perceptions of medicines containing
codeine across the UK.
▪ The study used a questionnaire design with
closed-ended and open-ended items relating to
prescribed and over-the-counter medicines con-
taining codeine and included questions on
dependence and treatment options in practice.
▪ Professionals involved in the prescribing of
codeine were accessed across the UK using the
principles of stratified random sampling.
▪ Response rates were lower than expected and
the study was unable to access the full popula-
tion of nurse prescribers.
▪ This study is cross-sectional and therefore does
not describe how the situation might change
over time.
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Treatment with opioid medication is thought to be
effective in the treatment of moderate pain for acute
and short periods of <6 months.7 Current scientiﬁc evi-
dence measuring the efﬁcacy of codeine over other
alternative medications for chronic and longer term
pain remains inconclusive.8 There are limited studies
examining the efﬁcacy of low doses of codeine found in
many prescribed and OTC medicines (<12.8 mg per
unit dose). While several Cochrane reviews have evalu-
ated the efﬁcacy of codeine, these are principally con-
ﬁned to acute postoperative pain at high doses (60 mg).
Some studies show codeine as clinically useful in some
patients. A Cochrane review using 14 studies comprising
926 participants compared the use of single-dose oral
paracetamol plus codeine with the same dose of para-
cetamol alone for postoperative pain in adults.
The review concluded that the addition of codeine
provided effective pain relief to ∼10% more participants
than the same dose of paracetamol alone. The use of
codeine in combination with paracetamol was found to
extend the duration of analgesia by ∼1 hour.9 A recent
Cochrane review found that the combination of ibupro-
fen 400 mg plus codeine 25.6–60 mg demonstrated
effective analgesic efﬁcacy in postoperative pain;
however, very limited data suggest that the combination
is better than the same dose of either drug alone.10
Equally, the use of codeine-containing syrups in supres-
sing cough appears to lack positive scientiﬁc basis and is
not widely discussed in the current literature.
While codeine is considered a weak opiate, it carries
an identiﬁed abuse potential. Development of tolerance
on regular or excessive use appears within a short time
frame.11 Literature reports increasing trends in the
misuse of codeine, including OTC preparations, which
appears to incur signiﬁcant negative epidemiological,
social and economic consequences.12–16 Related harms
in terms of morbidity and mortality are documented,12
along with monetary costs associated with indirect
effects on healthcare, prevention and treatment.17
Treatment of codeine dependence is varied and does
not appear to be well documented in the literature.
Guidance on options for opioid dependence is evident
but appears non-speciﬁc to weak opioids such as
codeine. Summary statistics for codeine dependence
obtained from treatment providers in the UK suggest
that codeine as the primary and secondary substance of
misuse is extremely low at 2.2% (4248 individuals) of all
those entering addiction treatment services in the
period 2013–2014.18 These statistics may give an impres-
sion that codeine dependence is not an issue warranting
attention compared with other substances of misuse;
however, treatment for codeine dependence conducted
in primary care does not appear in national treatment
surveillance systems. What is of particular concern is that
codeine-dependent patients appear to function well
within the range of perceived normality, carrying out the
functions of normal daily living.19 Evaluating as to
whether medical professionals are equipped to detect
and manage patients presenting with codeine depend-
ence is therefore an area of considerable importance.
Studies have called for further research on the experi-
ences and concerns of medical professionals around use
of medicines containing codeine, with particular focus
on their experiences, challenges, perspectives and prac-
tices.20 The aim of the study was to garner information
regarding prescribing practitioners’ perspectives on pre-
scribed and OTC codeine use, their ability to identify
dependence and options for treatment in the UK. This
study was part of a larger study examining OTC and pre-
scribed misuse of codeine medicines in the Republic of
Ireland, UK and South Africa and was funded by the
European Commission (http://www.codemisused.org).
METHOD
Recruitment of participants and study procedures
The study involved a cross-sectional design and took
place between May 2014 and April 2015 using an
online questionnaire (see ﬁgure 1). A nationally rep-
resentative sample of medical practitioners in the UK
was facilitated through Specialist Info, a medical direc-
tory specialist. A random list of 1000 practice man-
agers was generated by strata using proportionate
numbers of general practitioners (GPs) present in
each country (Wales n=48, Northern Ireland n=36,
Scotland n=98, England n=818). Each practice
manager was asked to recruit at least one GP from
their respective practice to participate in the study.
Each practice manager was sent a reminder ∼2–
4 weeks later. A total of 150 pain specialist physicians’
email records were also retrieved from Specialist Info
and these were subsequently sent the link to the
survey. In order to have representation from nurse
prescribers, a previous distribution list of 98 pain spe-
cialist nurses was used.21 These participants were
asked to indicate their agreement to be added to the
email distribution list. In total, 54 agreed to partici-
pate and the link to the survey was then provided. In
total, this process resulted in 136 participants com-
pleting the online questionnaire. A further 65 GPs
were recruited through GP target sessions. A second
random sample of 1000 practice managers was gener-
ated, checked for duplicates and emailed as previously
described. A follow-up reminder was distributed 4–
6 weeks later. This resulted in the completion of a
further 98 questionnaires. The indicated time to com-
plete the questionnaire was ∼10 min, and this was spe-
ciﬁed in the email correspondence and prior to
proceeding with the questionnaire. Information on
the study was provided and informed consent was
obtained prior to proceeding online. Participants
were advised to complete the questionnaire only once.
Dissemination activities, including circulars and news-
letters, were used to encourage participation in the
study. Ethical approval was granted by King’s College
London Ethics Committee (PNM/13/14-75).
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Data collection methods
We collected the data using an online questionnaire
using the survey tool http://www.onlinesurveys.ac.uk.
Questions were developed to bridge gaps in knowledge
following a comprehensive search of the literature.4
Eight questions were added to collect demographic
information in order to establish the representativeness
of the respondents. The questionnaire comprised a com-
bination of closed-ended and open-ended items, on pre-
scribed and OTC medicines containing codeine, and
included questions on triggers for suspecting codeine
misuse, managing codeine-dependent patients and
reasons for referral. Participants were provided with an
opportunity to add additional comments at the end of
the questionnaire and knowledge of innovations on pre-
venting medicine misuse (see online supplementary
information for full details of questionnaire). A paper
edition of the questionnaire was made available at GP
target sessions in two separate locations (continuing pro-
fessional development). GPs had the option to complete
the questionnaire online via the survey link or complete
the paper copy and return to the researcher at the end
of the target session. GPs were also informed that they
could return by post and were provide with a return
envelope on request.
Data analysis
Data were downloaded directly from the online data
capture page to SPSS V.21. Data captured in paper
format were entered manually and combined with the
data captured online. Data were screened and checked
for errors. Data were then examined descriptively using
Figure 1 Recruitment of participants to the study. GP, general practitioner.
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frequencies and percentage. The data were summarised
to create two categories by combining levels of agree-
ment and disagreement for reporting purposes. The
occurrence of codeine dependence was estimated using
the approximate numbers of patients suspected of
having codeine dependence as indicated in the ques-
tionnaire divided by the number of consultations indi-
cated by professionals in an average month. Referrals
were estimated using the numbers indicated by partici-
pants in the questionnaire, and this ﬁgure was presented
as an overall percentage of the total number of partici-
pants’ referrals to secondary care for codeine
dependence.
The open-ended questions were downloaded into a
separate Excel sheet for content analysis. These data
were examined and individual categories were created
for each of the open-ended questions based on common
features and dominant subjects identiﬁed in the text.
The categories were discussed by two senior members of
the research team and agreed. Three researchers inde-
pendently coded the data (two academic researchers
and one pharmacist). This was achieved by labelling
each ﬁeld where the content matched the associated
thematic category. Intercoder reliability of the data was
conducted by dialogue between three members of the
research team. Each item was checked for agreement
and non-agreement with the thematic categories. Where
discrepancies were identiﬁed or disagreement with the
category placing occurred, the researchers discussed the
illustrated content. This was then resolved when two or
more researchers were in agreement. Data were pre-
sented as an overall percentage of those who responded
to the open-ended questions.
RESULTS
Three hundred medical professionals involved in pre-
scribing codeine were recruited to the study, giving an
overall response rate of ∼12.5%. Table 1 details the
demographic information. The mean age of participants
was 47 years (range 25–68 years). The average number
of years of practice was 19.52 years (range 1–48 years).
Prescribed codeine
Figure 2 illustrates statement items examining medical
professionals’ experiences of prescribing codeine.
Percentage agreement and disagreement were used to
describe the results. In total, 50% of participants
showed some level of agreement that the requests for
prescribed codeine were increasing. In relation to pre-
scribing practices, 54% of participants implied that
they avoided the prescribing of codeine with other
depressant drugs. In total, 82% of participants agreed
to some extent that they prescribed codeine following
unsuccessful treatment with non-opioid analgesics.
Only 12.6% of participants agreed to prescribe codeine
cough linctus following unsuccessful treatment of
cough with non-codeine-based medicine. Less than
20% of participants agreed that low doses of codeine,
<30 mg, are not very effective in treating
mild-to-moderate pain. In total, 80% of professionals
agreed to routinely reviewing patients who are pre-
scribed codeine. In total, 27% of those responding
believed that patients resented them for asking about
their use of medicines containing codeine. However,
most professionals disagreed with the statement in
respect to ‘feeling awkward’ around questioning
patients about their codeine use (76.6%).
Furthermore, over half showed a level of disagreement
(53.7%) with the statement ‘patients are aware of the
adverse health consequences of high dose of combin-
ation codeine medicines’. Participants recognised the
potential for codeine to be used recreationally
(81.7%).
Table 1 Demographic details and information pertaining
to profession, location and specialist training
N=300
Frequency
(f)
Per
cent
Gender
Male 140 46.7
Female 160 53.3
Age Median 48 years,
range 25–68 years
Profession
General practitioner 238 79.3
Independent/supplementary/
nurse prescriberi
23 7.7
Specialist in family medicine 31 10.3
Specialist in pain management 0 0
Other 8 2.7
Number of years as a qualified
practitioner
Median 20 years,
range 1–48 years
Number of consultations in an
average week
Median 100, range
7–500
Country
England 253 84.6
Wales 15 5.0
Scotland 23 7.7
Northern Ireland 9 2.7
Location
Urban 166 55.3
Rural 40 13.3
Mix of both 94 31.3
Specialist training in substance misuse
Yes 89 29.7
No 208 69.3
Did not indicate 3 1.0
Type of substance misuse training
Certificate in substance misuse 42 47.2
Postgraduate qualification in
substance misuse
13 14.6
Continuing professional
development (CPD)
12 13.4
Other 5 6.3
Did not indicate 17 19.1
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OTC codeine
Figure 3 shows statement items examining medical pro-
fessionals’ experiences of OTC codeine. Percentage
agreement and disagreement were used to describe the
results. A total of 76% of those responding to the ques-
tionnaire were found to routinely ask about patients’ use
of OTC codeine medicine, and 71% indicated that they
documented the use of OTC medicines in the patients’
medical notes. Concern about availability of OTC
codeine in pharmacies was recorded at 45.8%. Concern
about the availability of OTC codeine on the internet
was slightly higher at 64%. However, the vast majority of
practitioners agreed to some extent that the potential to
buy codeine from multiple sources added signiﬁcantly
to the potential for misuse (86.9%). A total of 35%
showed some level of agreement that medicines contain-
ing codeine should be regulated to a prescription-only
medicine, while a similar percentage (36%) did not or
had no opinion (28%). A total of 16% of participants
felt that patients were given sufﬁcient information and
there was agreement that patients were not fully aware
of the risks of dependence with consumption of OTC
codeine medicines (83.8%) and believed them to be
safe (86.3%). Only 23% of practitioners agreed (or
strongly agreed) that codeine was more effective than
non-opioid analgesics. The potential to extract codeine
from compounded formulation showed mixed levels of
agreement.
Dependence, screening and treatment
Figure 4 shows responses to the various statement
items examining codeine dependence. Only 8% of
participants agreed that patients were not at risk of
codeine dependence when they took their codeine
medicine as prescribed. The majority agreed to some
extent that patients did not fully understand the risk of
dependence when taking prescribed medicine contain-
ing codeine (82%). Over 40% agreed the difﬁculty in
identiﬁcation of problematic use of codeine without
being informed by the patient. This corresponded with
relatively high percentages of those who did not feel
conﬁdent in identiﬁcation of codeine dependence
(41%). When asked if women were at higher risk of
development of codeine dependence, only 20.8%
agreed, while 16% showed a level of disagreement. A
total of 45% of all participants agreed that codeine
dependence could be managed effectively in general
practice.
A total 21% of participants agreed to have suitable
screening methods to identify if codeine was being used
inappropriately. A total of 27% of participants agreed
that adequate services were in place to manage codeine-
dependent patients, while only 28% agreed to be fully
aware of best practice in managing codeine misuse and
dependence. A high proportion of participants (70.3%)
would like more instruction on the prescribing of poten-
tially addictive medicines.
Managing codeine dependence
A total of 86% of the total participants had suspected
cases of codeine dependence in practice. The median
number of patients suspected of being codeine depend-
ent was calculated as being three patients per 100 con-
sultations. When asked if they had referred a patient to
Figure 2 The level of agreement (agree strongly, agree) and disagreement (disagree strongly, disagree) and neutral responses
with statements related to prescribed codeine medicine.
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Figure 4 The level of agreement (strongly agree, agree) and disagreement (strongly disagree, disagree) and neutral responses
with statement items related to codeine dependence and treatment. OTC, over the counter.
Figure 3 Percentages of agreement (strongly agree, agree) and disagreement (strongly disagree, disagree) and neutral
responses with each of the statements related to over-the-counter codeine.
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specialist care for codeine dependence in the past
month, 27% of participants indicated referrals to sec-
ondary/specialist care. Where referrals were indicated,
the median number was one patient in a monthly
period.
Patient behaviours, treatment options and referral reasons
Practitioners were asked to describe the typical patient
behaviours triggering their suspicion of codeine misuse.
Table 2 shows thematic categories of results displayed as
a frequency and as a percentage of the total responses.
Patient behaviours that triggered suspicion of codeine
misuse and dependency included requesting codeine
speciﬁcally by name, early requests and reﬁlls and
calling the surgery at inappropriate times to request
codeine medicines. The potential to obtaining codeine
from multiple sources was expressed. Additional
comments reﬂected the difﬁculties in managing
patients’ codeine use.
It is very difﬁcult to control patients’ codeine use as they
may use multiple pharmacies, buy from friends or online.
I don’t think we have fully woken up to the scale of the
problem of opiate dependence. Especially when opiates
are prescribed by pain clinics for chronic, non-cancer
pain. (GP participant)
Have advised colleagues many times that this is a time-
bomb (not wishing to be melodramatic!) If evidence is
promoted or the Daily Mail decides to champion a
codeine scare we will be on the back-foot managing the
fall-out and patient distress. (GP participant)
Lost prescriptions or medicines were also perceived to
be an indicator of dependence, and practitioners used
anecdotes to describe patient situations such as ‘the dog
ate my script’, ‘I lost my medication on the bus’ or ‘on
holiday’. Unresolved pain was indicated as a further
trigger in suspicion of dependence, and situations of
hypersensitivity to pain were described in terms of head-
ache, inadequate pain relief and indications of chronic
pain not being helped by the current medication
regime. Aberrant behaviours were described and
included aggression, demanding codeine, reluctance to
change medication and becoming very keen to obtain a
script. Physical signs of misuse included restricted
pupils, anxiety, constipation, gastric disturbances and
irritability. Other indicators included history of
comorbidity and history of addiction. Some professionals
also mentioned social and economic factors including
taking excessive sick leave and unemployment.
Various treatments for codeine dependence were
described by practitioners (see table 2). A large propor-
tion of respondents mentioned slow or gradual with-
drawal as the suggested treatment in managing
dependence. Education and counselling was also
emphasised and was more often suggested with gradual
withdrawal and restricted prescriptions. Additional com-
ments were also made about the area of practitioner
training in managing misuse and the requirement to
improve patient knowledge on codeine consumption.
It would be helpful to have some teaching on misuse of
OTC products and management there of. (GP
participant)
I am very concerned about the number of people I see
who take products containing a combination of codeine
and paracetamol at levels that put them at high risk of
liver damage as they often do not realise that taking large
amounts for the psychoactive effects of the codeine
means that they are likely to be unintentionally overdos-
ing on the paracetamol. (GP participant)
Restricted prescriptions were described in terms of
giving limited amounts of codeine in doses of up to
3 days or a 1-week supply. One GP spoke of the role of
Table 2 Main thematic categories and frequency of
responses
N=300
Frequency of
responses (%)
Can you describe the patient behaviours that trigger your
suspicion of codeine misuse?
Requesting prescriptions for codeine 212 (71)
Aberrant behaviour 89 (30)
Unresolved pain/cough 78 (19)
Lost prescriptions or medications 52 (17)
Physical or psychological symptoms 41 (14)
History of addiction 38 (13)
Doctor/pharmacy shopping for codeine
medicines
28 (9)
History of comorbidity 14 (5)
Socioeconomic status 14 (5)
Sex 3 (1)
Can you describe the types of treatments that you use for
patients with codeine dependence?
Slow or gradual withdrawal 153 (51)
Education/counselling 87 (29)
Referral to secondary or specialist
care
87 (29)
Restricted prescriptions 60 (20)
Substitution with another drug (drug
not specified)
30 (10)
Substitution using methadone/
buprenorphine/other opiate drug
27 (9)
Substitution with non-opioid
medication
15 (5)
Substitution using benzodiazepines/
other antipsychotics/other
15 (5)
Cold turkey 9 (3)
What were the main reasons for referring patients to
specialist treatment?ii
Failure to manage patient effectively in
practice
150 (50)
Complex case requiring specialist care 186 (62)
Patient request for referral 63 (21)
Lack of resources 45 (15)
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advertising and efforts to control repeat prescribing,
while another also spoke of the problems of monitoring
of repeat prescriptions.
We worry about codeine abuse, etc., yet Solpadeine is
very heavily advertised, but it does serve a purpose in self-
medication for moderate pain. In my experience patients
are started too early on high strength codeine painkillers
and simply parked there via repeat prescriptions. Little
effort seems to be given to follow up and monitoring
usage before the patient becomes addicted to the
codeine as opposed to suffering pain. (GP participant)
Big problem. We struggle to monitor repeat prescriptions
closely enough. Hospitals hand out codeine and trama-
dol like smarties. Difﬁcult to know how best to tackle
OTC access as primary care does not have the capacity to
pick up seeing all those people who self-treat appropri-
ately with OTC meds. (GP participant)
Other suggested treatments include substitution using
non-opioid analgesics, substitution with other drugs
including amitriptyline and benzodiazepines, other
opiates, methadone and buprenorphine. Some respon-
dents indicated that the main treatment they used was
‘cold turkey’. Referral to specialist care was also indi-
cated, including drug and alcohol services, rehabilitation
centres, psychologists, psychiatrists and pain specialists.
The primary reasons for referrals are reported in table 2
and were indicated as the inability to manage the patient
effectively in primary care or that the patient was a
complex case requiring specialist care. Complex cases were
described as those with multiple issues, including other
drugs and alcohol misuse, pregnant patients and other
comorbidities, usually related to mental health. Some senti-
ment was also expressed about other drugs of misuse.
Whilst codeine is misused, I am more concerned with
heroin and cocaine misuse. (GP participant)
We also have big problems with dihydrocodeine, oxy-
codone, tramadol, pregabalin and gabapentin. (GP
participant)
Patient’s request to be referred for specialist treatment
was also a common response. Indications were also that
referrals to specialist care were as a result of the lack of
resources, or time during the consultation and lack of
knowledge with regard to the best practice.
Some additional comments were made related to the
lack of resources available to manage the problem of
codeine dependence.
There is a gap between practicing perfect medicine
where patients’ drug use is explored in depth and the
practicalities of managing time and workload. I feel that
to a certain extent, exploring drug misuse in patients
who are pre-contemplative is not necessarily the most
effective use of time (although of course would be done
in an ideal world). (GP participant)
DISCUSSION
The current study exhibited high levels of agreement
that patients prescribed codeine were routinely reviewed
by their medical professional and included questioning
around OTC codeine use. Half of all those who
responded felt that the request for codeine medicines
was increasing and is substantial in raising some
concern. The increasing requests for codeine may be
directly as a result of newer restrictions imposed on
OTC supply, forcing patients to obtain a steady source
on prescription.21 Other factors contributing to the per-
ceived increase in codeine requests may relate to
changes in scheduling of other prescription opioids
such as tramadol.22 In the UK, tramadol must only be
supplied in quantities that do not exceed 30 days and
must not be dispended on ‘batch’ repeat prescriptions,
making reﬁlls more difﬁcult to obtain. Codeine is cur-
rently not bound by these restrictions. While there is no
speciﬁc evidence to verify that codeine consumption is
increasing, a level of caution should be exercised by the
prescriber when a medicine is requested speciﬁcally by
name. Content analysis of the open-ended questions
showed that one of the most common triggers for sus-
pecting misuse was when codeine was requested speciﬁc-
ally by its name or brand name.
Views regarding the effectiveness of 30 mg of codeine
showed some notable variation. The efﬁcacy of low
doses of codeine is not well documented in the litera-
ture and a greater evidence base is required to further
develop indications for codeine use.23 Prescribing of
codeine was indicated following unsuccessful treatment
with non-opioid analgesics. However, the complexity of
pain management has drawn signiﬁcant attention over
recent years with limited options for prescribers to avoid
unpleasant side effects.24 25 Newer drugs acting at the
γ-aminobutyric acid (GABA) receptors have gathered
some momentum in the treatment of chronic neuro-
pathic pain; however, they also carry signiﬁcant side
effects and serious risk of misuse.26 The difﬁculty for any
prescriber is to balance the beneﬁts and risks of opioid
use and it is feasible that codeine is considered to have
lower abuse liability due to it weak opioid status.27
There is concern regarding patients’ use of OTC
codeine-containing medicine, and a large number of
respondents in the current study believe that patients
were unaware of the health consequences associated
with high doses of combination codeine preparations.
Equally, the respondents were of the view that patients
do not understand the risk of dependence when taking
prescribed medicines containing codeine. This concurs
with evidence reported in the literature.28 29 Further
research should identify the level and type of informa-
tion patients require to make informed decisions sur-
rounding their medicine use, both prescribed and OTC.
Rescheduling of codeine has drawn signiﬁcant debate
and some suggestion was made in the current study to
remove sales of OTC codeine altogether.24 However,
without actual prevalence rates of misuse and harm, it is
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difﬁcult to draw deﬁnitive conclusions. Equally, other
prescription opioids, including codeine, are also
misused, so removal of OTC codeine is unlikely to elim-
inate the problem entirely. Additionally, several coun-
tries across the European Union (EU) do not permit
the sale of OTC codeine,25 and there is little evidence
that restricting this provision has any impact on harms
associated with its use. The rescheduling to a
prescription-only medicine is likely to place additional
pressure on GPs for self-limiting conditions and shift
diversionary patterns. This may explain differences
observed in the current study regarding rescheduling of
codeine to a prescription-only medicine.
Risk of development of a codeine dependence in spite
of taking codeine as prescribed was identiﬁed by the
majority of professionals in the UK and shows that pre-
scribers are aware of potential risks associated with its
use. Detection of codeine dependence in patients
appears to be problematic, with low levels of conﬁdence
expressed in detection of codeine dependence, high-
lighting the need for speciﬁc screening tools.30 Equally,
adequate screening tools for identiﬁcation of patient at
risk appear lacking in practice, and practitioners indi-
cated the desire for further training activities on pre-
scribing potentially addictive medicines. Education of
professionals on the abuse potential of codeine and the
ability for individuals to extract paracetamol from com-
pounded formulations is also warranted to enhance
existing knowledge.
Currently, there are no speciﬁc clinical guidelines on
managing codeine detoxiﬁcation, although clinical guid-
ance does exist under the broad umbrella of opioid
detoxiﬁcation.31 In the current study, an overwhelming
majority of respondents indicated that they used the
process of gradual withdrawal including tapering of the
dose, restricting and reducing patients’ prescriptions
coupled with education and counselling techniques as
strategies to address misuse of and dependence on
codeine. A minority of participants mentioned that they
would prescribe benzodiazepines and other medicines
to manage codeine-dependent patients. The basis of this
decision should be investigated further in light that
some of the drugs mentioned come with a high abuse
potential. The methods offered by respondents may well
be the foundation on which to build some guidance for
prescribers and pharmacists in managing detoxiﬁcation,
however, taking into consideration that each patient will
have their own individual needs. Owing to the fact that
several of the prescribers mentioned the toxicity asso-
ciated with paracetamol and ibuprofen, initial treatment
to reduce this risk should be the ﬁrst consideration.11
The education and counselling offered and expressed
by professionals in the open-ended questions could be
further evaluated for its content, applicability and effec-
tiveness in the treatment process.
Levels of referral to secondary care appear low and
reﬂect the levels of patients entering addiction treatment
indicated by the National Drug Treatment Monitoring
Service,18 and may indicate that a high proportion of
patients are being effectively managed in primary care,
or more seriously, not being detected at all. If this is the
case, then actual prevalence rates of misuse are under-
reported in the national ﬁgures. The reporting of
codeine misuse by general practice outside of secondary
care may actually help in the estimation and prevalence
of codeine and other substances of misuse in populations
who remain outside of addiction services. Professionals in
the current study identiﬁed a lack of support services for
those identiﬁed with problems related to their codeine
use. The acknowledgement of poor support requires
further investigation in the context of the development
of adequate services for patients within primary care,
community and inpatient settings.
LIMITATIONS
There are several limitations with respect to this study.
The recruitment of participants to this online survey was
challenging and therefore resulted in a lower than
expected response rate. The targeting of GP practice
managers rather than GPs directly may have impacted
on the response rate. However, due to the level of email
correspondence GPs receive, ﬁltering it in this manner
may have been beneﬁcial. There may be some criticism
of the methods used to boost response; however, as a
professional group, it is unlikely that participants
answered the questionnaire more than once. The study
is cross-sectional in nature and therefore cannot
describe how the situation might change over time. It is
also possible that those experiencing problem with
codeine dependence in their practice may have been
more likely to participate in the study. It is possible that
the term misuse and dependence may have different
meanings to speciﬁc responders, and while speciﬁc deﬁ-
nitions were provided, these were contained within an
additional information drop-down menu. However, one
of the major strengths of the study is the fact that it
responds to the increasing demand for greater informa-
tion regarding codeine misuse and dependence found
in the UK and provides information that can be used in
future studies.
IMPLICATIONS FOR PRACTICE
Greater sources of information are required to develop
policy on codeine use, misuse and treatment options in
the interest of public health. This study has shed light
on medical professionals’ experiences in the UK and
has highlighted areas of concern regarding medicines
containing codeine and the need to develop speciﬁc
patient screening tools. It is important to note that med-
icines containing codeine have utility when used appro-
priately; however, greater research is required to
examine its indications for use in longer term pain man-
agement. Further education and training is required in
the area of prescribing addictive medicines at all levels
of practice. Similarly, specialist training on recognition
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of the signs and symptoms drawn from the responses of
professionals in this study could help with early detec-
tion of codeine dependence. The reporting of cases of
codeine dependency outside of addiction services into
national registers should be considered. It is important
to identify as accurately as possible the prevalence of
codeine misuse and dependence in the population so
that services can be adequately provided and needs
addressed appropriately.
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